Mylan Pays $9M To Settle Paclitaxel Patent Suit
Mylan, the largest maker of generic drugs in the U.S., said the payment will end a lawsuit pending in federal court in Pittsburgh. Under the settlement, Mylan will have a paid-up license to sell paclitaxel under Mayne's patents.
“The parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western District...
To view the full article, register now.